ReviewDiscover oncology2026
A comprehensive analysis and visualization of immune-related adverse events in lung cancer immunotherapy a bibliometric study.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune-related adverse events (irAEs) significantly impact the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in lung cancer. However, a comprehensive understanding of the global research landscape and its evolution regarding irAEs is still lacking.
methodsWe conducted a bibliometric analysis of 6787 publications from the Web of Science Core Collection (2015-2024) via CiteSpace and the R-bibliometrix package. The analyses included cocitation, coauthorship, and keyword burst detection to map collaborative networks, knowledge structure, and research trends.
resultsResearch output demonstrated a remarkable compound annual growth rate of 30.4%. INSERM (France) and US institutions appeared as central hubs in collaborative networks, whereas China-despite its high publication volume-showed more limited international integration, suggesting a productivity‑influence mismatch. The knowledge base comprises three clusters: clinical evidence, translational research, and fundamental immunology. Research themes evolved from initial tumor-agnostic safety reports to a focus on organ-specific irAEs and precision toxicology.
conclusionThis study delineates the rapidly evolving landscape of irAE research in lung cancer immunotherapy, highlighting key collaborative patterns, knowledge structures, and thematic shifts. The findings provide a foundational perspective for guiding future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.